SER

1.1206.67%
ST

Srini Tenjarla

Chief Technical Operations Officer

Dr. Srini Tenjarla, Ph.D., serves as Chief Technical Operations Officer at Serina Therapeutics, Inc. since March 2026 and served as its Senior Vice President of Chemistry, Manufacturing & Controls and Formulation from July 2024 until March 2026. Dr. Tenjarla has extensive experience in drug development to Serina. Dr. Tenjarla joined Serina Therapeutics in July 2024 from Takeda Pharmaceuticals, where he served as Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing in Pharmaceutical Sciences. In this role, he provided technical and strategic leadership to global teams, overseeing phase-appropriate development from Phase 1 through product validation and PAI readiness. Prior to his tenure at Takeda, Dr. Tenjarla held several leadership roles at Shire Pharmaceuticals, culminating in his position as Vice President of Pharmaceutical Sciences. Dr. Tenjarla has a proven track record in advancing programs through clinical phases to NDA/BLA submission and approval. Throughout his career, Dr. Tenjarla has demonstrated expertise in formulation development across multiple modalities, including solid oral, injectables, controlled release and ophthalmic formulations. He has led numerous global cross-functional teams and collaborated with CDMOs in Europe, the USA, China, India and Japan. His contributions include setting up Preferred Vendor Networks and working closely with device and quality groups for combination product programs. Dr. Tenjarla holds a Ph.D. in Pharmaceutical Sciences from the University of Houston and a Bachelor of Science in Pharmacy from Andhra University. He is a recognized subject matter expert in formulation, with extensive experience managing programs, formulation, drug substance, analytical and regulatory interactions.

Positions